Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The Alberta Blue Cross report notes that several notable generic medications and biosimilars under Health Canada review could provide significant cost savings for plan sponsors, though the insurer's overall view is that GLP-1 category spend will remain elevated as utilization broadens
These combinations increase total monthly medication cost
However, with few clinical trials, it requires consistent, long-term use to achieve and sustain results
It modulates insulin receptor sensitivity and reduces hepatic lipogenesis in insulin-resistant states
:format(webp))
US$ 20.72
US$ 20.57
US$ 21.91
US$ 21.20
